07:00 , May 9, 2013 |  BC Innovations  |  Targets & Mechanisms

AD vaccine redux

Researchers at Harvard Medical School have teamed up with vaccine maker Mercia Pharma Inc. to design a next-generation Alzheimer's disease vaccine with an adjuvant that promotes a beneficial anti-inflammatory response that the team hopes will...
07:00 , May 31, 2010 |  BioCentury  |  Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
07:00 , Sep 3, 2007 |  BioCentury  |  Strategy

Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
07:00 , Mar 12, 2007 |  BC Week In Review  |  Company News

t2cure management update

t2cure GmbH , Frankfurt, Germany   Business: Gene/Cell therapy   Hired: Manfred Ruediger as CEO, formerly COO of Aphton Corp.  ...
01:30 , Mar 9, 2007 |  BC Extra  |  Company News

t2cure names Ruediger CEO

t2cure (Frankfurt, Germany) hired Manfred Ruediger as CEO, a new position at the regenerative medicine company. Previously, he was COO of Aphton (APHTQ)....
07:00 , Aug 7, 2006 |  BC Week In Review  |  Company News

Aphton, Receptor BioLogix deal

Receptor BioLogix acquired APHTQ's Insegia (G17DT) cancer vaccine in a Chapter 11 bankruptcy sale. Receptor BioLogix said it expects to pay no more than $1 million for the product and related assets. The company plans...
07:00 , May 29, 2006 |  BC Week In Review  |  Company News

Aphton cancer news

APHT filed for Chapter 11 bankruptcy. The company discontinued lead compound Insegia (G17DT) last May after it missed the primary endpoint of overall survival in a Phase III trial to treat pancreatic cancer. APHT's IGN101...
07:00 , May 29, 2006 |  BioCentury  |  Product Development

Late-stage cancer vaccines

Late-stage cancer vaccines Company Product Description Indication Status Trial details Accentia BiovaxID Vaccine containing tumor-specific idiotype protein from the patient's lymphoma cells and conjugated to Keyhole-Limpet- Hemocyanin (KLH), an adjuvant to stimulate an immune response...
07:00 , May 29, 2006 |  BioCentury  |  Product Development

Cancer vaccines in development

Cancer vaccines in development Company Product Description Indication Status Avax/Pro Vaccine/Australian Vaccine Tech M-Vax Autologous haptenized tumor cell vaccine Stage III and IV melanoma Compassionate use in France, Spain and Belgium; Ph I/II in U.S....
08:00 , Feb 20, 2006 |  BC Week In Review  |  Company News

Aphton, Kyowa Hakko Kogyo Ltd. deal

Kyowa's BioWa subsidiary granted APHT's Igeneon subsidiary a non-exclusive license to Potelligent technology to improve the antibody-dependent cellular cytotoxicity of Igeneon's IGN312 next-generation Lewis Y-specific antibody. Financial terms were not disclosed. APHT's IGN311 humanized monoclonal...